ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Vigil Neuroscience Inc

Vigil Neuroscience Inc (VIGL)

3.99
0.08
(2.05%)
At close: July 23 4:00PM
3.99
0.00
( 0.00% )
After Hours: 4:30PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.99
Bid
3.89
Ask
4.07
Volume
97,335
3.82 Day's Range 4.05
2.47 52 Week Range 9.24
Market Cap
Previous Close
3.91
Open
3.84
Last Trade Time
16:27:54
Financial Volume
$ 383,537
VWAP
3.9404
Average Volume (3m)
585,303
Shares Outstanding
37,584,312
Dividend Yield
-
PE Ratio
-1.81
Earnings Per Share (EPS)
-2.2
Revenue
-
Net Profit
-82.64M

About Vigil Neuroscience Inc

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple ther... Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
1970
Vigil Neuroscience Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIGL. The last closing price for Vigil Neuroscience was $3.91. Over the last year, Vigil Neuroscience shares have traded in a share price range of $ 2.47 to $ 9.24.

Vigil Neuroscience currently has 37,584,312 shares outstanding. The market capitalization of Vigil Neuroscience is $146.95 million. Vigil Neuroscience has a price to earnings ratio (PE ratio) of -1.81.

VIGL Latest News

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule...

Vigil Neuroscience to Present in Upcoming June Investor Conferences

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.21-54.24.43.5952739593.93695341CS
40.112.835051546393.884.773.5113030594.34396937CS
121.3953.46153846152.66.062.475853034.25052798CS
260.9732.1192052983.026.062.473139354.07399333CS
52-3.26-44.96551724147.259.242.472004974.15889664CS
156-8.01-66.751218.272.181152505.93923575CS
260-8.01-66.751218.272.181152505.93923575CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NIVFNewGenIvf Group Ltd
$ 1.42
(63.05%)
743.88k
ALLRAllarity Therapeutics Inc
$ 0.268
(60.96%)
21.07M
DRMADermata Therapeutics Inc
$ 1.48
(13.85%)
77.44k
SLNASelina Hospitality PLC
$ 0.0291
(11.92%)
22.4M
HOLOMicroCloud Hologram Inc
$ 0.6351
(8.60%)
4.99M
VSTMVerastem Inc
$ 2.60
(-27.58%)
261.56k
TCJHTop KingWin Ltd
$ 0.32
(-17.18%)
226.73k
SLRXSalarius Pharmaceuticals Inc
$ 2.20
(-15.71%)
101.28k
ALPPAlpine 4 Holdings Inc
$ 0.5229
(-12.84%)
254.03k
CJETChijet Motor Company Inc
$ 4.49
(-11.61%)
76.86k
SLNASelina Hospitality PLC
$ 0.0291
(11.92%)
22.4M
ALLRAllarity Therapeutics Inc
$ 0.268
(60.96%)
21.07M
TSLATesla Inc
$ 240.1105
(-2.54%)
7.76M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 13.0099
(-5.04%)
5.79M
HOLOMicroCloud Hologram Inc
$ 0.6351
(8.60%)
4.99M

VIGL Discussion

View Posts
Monksdream Monksdream 3 weeks ago
VIGL under $5
👍️0
MiamiGent MiamiGent 3 weeks ago
Good insight.
👍️0
Zorro Zorro 4 weeks ago
More than likely there is an announcement baked into this deal that will allow for the sale of those 7.44 shares at a profit.
👍️ 1
PonkenPlonken PonkenPlonken 4 weeks ago
Those 3.80 dippers look pretty smart now ;)
👍️ 1
MiamiGent MiamiGent 4 weeks ago
$VIGL At 12 noon:

Volume
13,927,465
90 Day Avg. Vol.
147,064

9.5 X's 90 DAV
👍️0
MiamiGent MiamiGent 4 weeks ago
VIGL Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GLOBENEWSWIRE
2:00 AM ET Jun-27-2024
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-

- Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies -

- Company expects proceeds to extend cash runway into 2026 -

WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL.NaE) , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.

“We are excited by this strategic investment from Sanofi, one of the world’s leading biopharmaceutical companies, for our research and development programs,” said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We view Sanofi’s investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG-3927, and Sanofi has provided valuable capital to help fund our pipeline. We look forward to the opportunity to work with Sanofi as we continue to advance our small molecule TREM2 agonist program.”

“Recent discoveries have highlighted the role of microglial signaling and neuroinflammation in neurodegenerative diseases. TREM2 is a well credentialed microglia target in this context,” said Erik Wallstroem, Sanofi's Global Head of Neurology Development. “The investment in Vigil strengthens our commitment to immunoscience and neuroimmunology.”

In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company’s small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer’s disease.

Based on current projections, the Company expects that the proceeds from Sanofi’s investment will extend its cash runway into 2026.

About Vigil Neuroscience (VIGL.NaE)

Vigil Neuroscience (VIGL.NaE) is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” of Vigil Neuroscience (VIGL.NaE) (“Vigil” or the “Company”) that are made pursuant to the safe harbor provisions of the federal securities laws.......
👍️0
PonkenPlonken PonkenPlonken 4 weeks ago
they often do this in bio land on those that open a quarter+ up, reverse to 0 and then let them go the days after
👍️ 1
PonkenPlonken PonkenPlonken 4 weeks ago
agree looking good down here
👍️0
MiamiGent MiamiGent 4 weeks ago
VIGL In @ 3.83 for the scalp
👍️0
reena969 reena969 4 weeks ago
VIGL: My guess is that the $7 price target for VIGL will be set for the 9:30 market opening, allowing the algorithm to gradually move it to that price point. 1498 in free left, I'll check back later.
Happy Trading
👍️0
tw0122 tw0122 4 weeks ago
VIGL chop zone makes sense just read news $7.44 max pain 4.80- 7.41 chop zone

Vigil Neuroscience, Inc. (VIGL) announces that Sanofi (SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company's small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer's disease.Based on current projections, the Company expects that the proceeds from Sanofi's investment will extend its cash runway into 2026.
👍️0
reena969 reena969 4 weeks ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665212

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665196
👍️0
tw0122 tw0122 4 weeks ago
VIGL 5.50s
👍️0
Monksdream Monksdream 2 months ago
VIGL under $5
👍️0
Monksdream Monksdream 3 months ago
VIGL under $3
👍️0
Terpi Terpi 8 months ago
This one trades this, looks like it may be finding a bottom.
👍️0

Your Recent History

Delayed Upgrade Clock